<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953547</url>
  </required_header>
  <id_info>
    <org_study_id>RAP</org_study_id>
    <nct_id>NCT03953547</nct_id>
  </id_info>
  <brief_title>Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization</brief_title>
  <acronym>RAP</acronym>
  <official_title>Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In coronary pathology, persistent platelet hyperresponsiveness under antiplatelet therapy,
      which is often referred to as &quot;antiplatelet resistance,&quot; is predictive of increased risk of
      thrombotic recurrence as well as hyper-Inhibition of this aggregation may be predictive of a
      hemorrhagic risk. But no study has shown that the adaptation of treatment based on platelet
      aggregation tests has a benefit: the management of antiplatelet treatments through the search
      for antiplatelet resistance (APR) is not recommended by the European Society of Cardiology
      (ESC) in the context of coronary angioplasty (IIIA), while this is a common practice in
      neurovascular pathology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In peripheral arterial disease, several studies have shown that the existence of an APR is
      predictive of the occurrence of thrombotic events but not all. The investigators can
      therefore ask the question of the benefit of adaptation of antiplatelet therapy by biological
      monitoring to prevent the recurrence of thrombotic events. The platelet aggregation tests
      used mainly concern aspirin, via stimulation with arachidonic acid, or anti-P2Y12
      (clopidogrel, ticagrelor, prasugrel), via stimulation with adenosine diphosphate (ADP). For
      the latter, a test via the measurement of the phosphorylation of a cytoplasmic protein called
      &quot;VASP&quot; is also used routinely, making it possible to further clarify the existence of
      platelet resistance to anti-P2Y12. Within the vascular medicine department, any discovery of
      a potential resistance to the anti-platelet treatment of a patient requires a therapeutic
      adaptation to overcome this phenomenon of &quot;resistance&quot;, and to improve the phenomenon of
      anti-aggregation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of re-occlusion of the revascularization procedure</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cardiovascular events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">88</enrollment>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>search for antiplatelet resistance</arm_group_label>
    <description>Patients who were hospitalized in the vascular medicine department and who benefited from a search for antiplatelet resistance between April 2014 and November 2017.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were hospitalized in the vascular medicine department and who received a
        search for antiplatelet resistance between April 2014 and November 2017.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  All patients who were hospitalized in the vascular medicine department and who
             received a search for antiplatelet resistance between April 2014 and November 2017.

        Exclusion Criteria:

          -  Opposition to participation in the study

          -  Absence of follow-up after antiplatelet resistance testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphaël ATTAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Paris Saint Joseph</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x.</citation>
    <PMID>22260716</PMID>
  </results_reference>
  <results_reference>
    <citation>Pinto Slottow TL, Bonello L, Gavini R, Beauzile P, Sushinsky SJ, Scheinowitz M, Kaneshige K, Xue Z, Torguson R, Tantry U, Pichard AD, Satler LF, Suddath WO, Kent K, Gurbel P, Waksman R. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol. 2009 Aug 15;104(4):525-30. doi: 10.1016/j.amjcard.2009.04.015. Epub 2009 Jun 24.</citation>
    <PMID>19660606</PMID>
  </results_reference>
  <results_reference>
    <citation>Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.</citation>
    <PMID>28886622</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta R, Moore JM, Griessenauer CJ, Adeeb N, Patel AS, Youn R, Poliskey K, Thomas AJ, Ogilvy CS. Assessment of Dual-Antiplatelet Regimen for Pipeline Embolization Device Placement: A Survey of Major Academic Neurovascular Centers in the United States. World Neurosurg. 2016 Dec;96:285-292. doi: 10.1016/j.wneu.2016.09.013. Epub 2016 Sep 15.</citation>
    <PMID>27641263</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazur P, Frołow M, Niżankowski R, Sadowski J, Undas A. Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. Platelets. 2013;24(2):151-5. doi: 10.3109/09537104.2012.676220. Epub 2012 Apr 13.</citation>
    <PMID>22497730</PMID>
  </results_reference>
  <results_reference>
    <citation>Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997 Sep;78(3):1003-7.</citation>
    <PMID>9308744</PMID>
  </results_reference>
  <results_reference>
    <citation>Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical implications of aspirin resistance. J Vasc Surg. 2009 Dec;50(6):1500-10. doi: 10.1016/j.jvs.2009.06.023. Epub 2009 Aug 12. Review.</citation>
    <PMID>19679423</PMID>
  </results_reference>
  <results_reference>
    <citation>Doly JS, Lorian E, Desormais I, Constans J, Bura Rivière A, Lacroix P. [Prevalence and prognosis of aspirin resistance in critical limb ischemia patients]. J Mal Vasc. 2016 Dec;41(6):358-364. doi: 10.1016/j.jmv.2016.08.004. Epub 2016 Oct 14. French.</citation>
    <PMID>27745943</PMID>
  </results_reference>
  <results_reference>
    <citation>Navarese EP, Wernly B, Lichtenauer M, Petrescu AM, Kołodziejczak M, Lauten A, Frediani L, Veulemanns V, Wanha W, Wojakowski W, Lesiak M, Ferrante G, Zeus T, Tantry U, Bliden K, Buffon A, Contegiacomo G, Jung C, Kubica J, Pestrichella V, Gurbel PA. Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. Int J Cardiol. 2018 Oct 15;269:292-297. doi: 10.1016/j.ijcard.2018.07.009. Epub 2018 Jul 3.</citation>
    <PMID>30045826</PMID>
  </results_reference>
  <results_reference>
    <citation>Soden PA, Zettervall SL, Ultee KH, Landon BE, O'Malley AJ, Goodney PP, DeMartino RR, Arya S, Schermerhorn ML; Society for Vascular Surgery Vascular Quality Initiative. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg. 2016 Dec;64(6):1633-1644.e1. doi: 10.1016/j.jvs.2016.05.098. Epub 2016 Aug 27.</citation>
    <PMID>27575814</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiplatelet resistance</keyword>
  <keyword>peripheral arterial revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

